Advances In Wound Healing And Surgical Scar Reduction

To Be Discussed in Hot Topics Seminar, April 21

ORLANDO, FL (April 21, 2006) – Two new products, that hold promise in surgical scar prevention and wound closure will be discussed, debated and evaluated by some of the world’s leading plastic surgeons at this year’s Hot Topics seminar at the Annual Meeting of the American Society for Aesthetic Plastic Surgery (ASAPS), April 21-25 in Orlando, FL.

Juvista, currently in phase II clinical trials in the UK, is an injectable that is placed in wounds at the time of closure in an effort to decrease scarring. The pharmaceutical product consists of TGF BETA-3 (Transforming Growth Factor Beta 3), a naturally occurring protein that is present in high levels in the embryo -- because of its involvement in skin development -- and in low levels in adults. The trials to date show promise, as the application of the product reportedly produces marked improvements in scar structure and color and in some cases the absence of scaring altogether.

Insorb, is a subcuticular skin stapler designed to combine the cosmetic result of absorbable sutures with the rapid closure times associated with metal skin staplers, while eliminating the need for metal staple removal post-operatively. It is comprised of a co-polymer of polylactic acid and polyglycolic acid, which is absorbed over a period of a few months. The product could eliminate the need for metal staple removal post-operatively in the aesthetic patient.

“Presentations at the Hot Topics seminar focus on the most promising innovations” said Jeffrey Lang, MD, president of the Aesthetic Surgery Education and Research Foundation (ASERF), co-sponsor of Hot Topics with the Plastic Surgery Educational Foundation (PSEF). “Certainly these two products will be widely discussed and debated on issues of safety and efficacy along with many other techniques and devices that have been recently developed, recently launched or are pending FDA approval.” he added.

“New innovations always come up against a legitimate concern for patient safety and are put to rigorous testing said V.Leroy Young, MD, Chair of the Emerging Trends Task Force co-sponsored by the Aesthetic Surgery Education and Research Foundation (ASERF) and the Plastic Surgery Educational Foundation (PSEF).

If products like Juvista and Insorb live up to their potential, they could be important tools in the aesthetic surgeon’s armamentarium eliminating scarring and painful staple removal, two of patients’ biggest concerns.”


The American Society for Aesthetic Plastic Surgery (ASAPS), is recognized as the world's leading organization devoted entirely to aesthetic plastic surgery and cosmetic medicine of the face and body. ASAPS is comprised of over 2,600 Plastic Surgeons; Active Members are certified by the American Board of Plastic Surgery (USA) or by the Royal College of Physicians and Surgeons of Canada and have extensive training in the complete spectrum of surgical and nonsurgical aesthetic procedures. International Active Members are certified by equivalent boards of their respective countries. All members worldwide adhere to a strict Code of Ethics and must meet stringent membership requirements.


Copyright © 2009-2017 ASAPS. All Rights Reserved.